The lore of Once Upon a Time in Shaolin, once bought by Martin Shkreli, is explored in a rambling film produced by RZA

For every reason except one, Once Upon a Time in Shaolin, the seventh album by the Wu-Tang Clan, should’ve been a commercial hit. The 31-track double album, recorded in secret between 2007 and 2013, reunited all of the remaining members of the hallowed Staten Island rap crew and featured eye-catching collaborators from the standard (Redman, offshoot group Wu-Tang Killa Bees) to the unexpected (Cher, Game of Thrones actor Carice van Houten). The sound, at least according to those involved, harkened back to the glory days of the group’s beginnings in the 90s.

But for years, almost no one heard it. The group only issued a single copy of Once Upon a Time in Shaolin – on CD, ensconced within layers of filigreed silver – with the stipulation, in legalese, that it could not be used for any commercial purposes for 88 years. The decree, either a stunt or a bold artistic statement on streaming’s devaluation of music, depending on your generosity and perhaps your net worth, succeeded in drumming up plenty of hype. And if you were anywhere around the blogosphere or cable news in 2015, you may recall that the beneficiary of that hype – the purchaser and thus single intended listener of this $2m musical treasure – was one Martin Shkreli, the “pharma bro” widely despised for gleefully hiking the costs of prescription drugs for profit.

Martin Shkreli—the ex-pharmaceutical executive infamous for illegally hiking the price of a lifesaving anti-parasitic drug by more than 4,000 percent and getting a seven-year prison sentence for the fraudulent scheme he used to do it—has been under a lifetime ban from the pharmaceutical industry since 2022.

However, according to the Federal Trade Commission and the attorneys general of seven states, Shkreli has "flagrantly and repeatedly" violated that ban nearly the entire time—allegedly by trading stock in dozens of drug companies and discussing the industry during livestreams on social media.

On Tuesday, the FTC and the seven states asked a federal judge to hold Shkreli in contempt for the alleged violations. The states include New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia—the same states that joined the FTC in suing Shkreli in 2020 over the "elaborate anticompetitive scheme" involving the anti-parasitic drug, Daraprim. The scheme raised the price from $17.50 per pill to $750 per pill virtually overnight, while blocking generic competitors from entering the market.

Read full article

Comments